Last reviewed · How we verify
HCP1102Placebo+HGP0711
HCP1102 is a dual GLP-1/GIP receptor agonist combined with HGP0711 (a GLP-1 receptor agonist) to enhance glucose control and weight loss through incretin mimicry.
HCP1102 is a dual GLP-1/GIP receptor agonist combined with HGP0711 (a GLP-1 receptor agonist) to enhance glucose control and weight loss through incretin mimicry. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | HCP1102Placebo+HGP0711 |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | Dual GLP-1/GIP receptor agonist |
| Target | GLP-1 receptor, GIP receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | Phase 3 |
Mechanism of action
This combination therapy activates both GLP-1 and GIP receptors, which stimulate insulin secretion in response to glucose, inhibit glucagon release, and promote satiety. The dual agonism provides synergistic effects on glycemic control and body weight reduction compared to single-agent GLP-1 agonists. The placebo control arm is used for comparative efficacy assessment in the phase 3 trial.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HCP1102Placebo+HGP0711 CI brief — competitive landscape report
- HCP1102Placebo+HGP0711 updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI